Clinical trials: Bortezomib
Multiple Myeloma
An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade
The purpose of this study is to acquire information on the usage, effectiveness, safety, and levels of health care resource utilization associated with Velcade therapy in recurrent and refractory multiple myeloma patients who are…
- Trial name
- NCT01675245
- Testing
- No intervention
- Volunteers
- 532 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
AL Amyloidosis
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
AL amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04304144
- Testing
- CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Multiple Myeloma, Refractory
Alvocade® (Bortezomib) Safety and Effectiveness Study
This study is a phase IV, post-marketing, observational, cohort study for safety and effectiveness evaluation of Alvocade® use in Iranian patients with multiple myeloma. No control groups were considered in the study design.
- Trial name
- NCT06012383
- Testing
- Bortezomib
- Volunteers
- 57 people
- Sponsor
- NanoAlvand
Multiple Myeloma
A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE
The purpose of this study is to give patients who have had 4 or more prior lines of therapy for multiple myeloma access to VELCADE.
- Trial name
- NCT00063791
- Testing
- Bortezomib
- Where
- 3 sites in United States
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
This study will compare the efficacy of PS-341 versus high dose dexamethasone.
- Trial name
- NCT00048230
- Testing
- bortezomib
- Where
- 93 sites in United States, Austria and 11 more
- Volunteers
- 620 people
- Sponsor
- Millennium Pharmaceuticals, Inc.